The External Automatic Glaucoma Laser (EAGLE) device has been developed and patented by BELKIN Laser (partner BEL) with the vision of providing a world-wide , cost-effective solution that enables an accessible first-line choice of treatment for glaucoma by an innovative one-second automatic laser treatment for the benefit of both ophthalmologists and patients. This novel, non-contact method  directs the beams deep into the sclera (the white part of the eye) around the limbus (the border between the colored and the white parts of the eye), a location which overlies the target tissue (trabecular meshwork). The instrument delivers about 100 laser applications automatically and simultaneously. This will enable treatment by this novel cost-effective device to be completed in less than one second in an automatic mode implementing image-acquisition technology, and could be performed by any ophthalmologist, not only glaucoma specialist. Thus, the clinical use of EAGLE will allow the world’s 212,000 eye doctors to offer laser therapy as a primary treatment for glaucoma, thereby overcoming the grave availability and compliance problems associated with eye drop therapy. The innovative technology provides a solution not only for Open Angel Glaucoma (OAG, 74% of total glaucoma cases) but may also serve as an exclusive solution for Angle Closure Glaucoma (ACG, ~26%). ACG is most common among East Asian and Indian populations and is the leading cause of irreversible blindness in China.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement

No 720274

September 22, 2016

Please reload

Last News  

  web design: STUDIO81